ArcticZymes Technologies (AZT) investor relations material

Executive summary

• Q1 2026 delivered record revenue of NOK 35 million, up 41% year-over-year, with strong momentum in Molecular Tools and Biomanufacturing, marking the strongest Q1 on record outside COVID.

• EBITDA turned positive at NOK 1.6 million, a NOK 5.3 million improvement from Q1 2025, and net profit reached NOK 0.6 million versus a loss last year.

• Strategic milestones included a European patent for RNA restriction enzymes, validation from key partners, and expanded collaborations.

• The business is transitioning to a customer-centric, application-led solutions provider, driving diversification and resilience.

• Positioned as a leader in viral vector manufacturing and RNA therapeutics through innovation and partnerships.

Financial highlights

• Sales revenue was NOK 31.8 million, up 36% year-over-year; at constant currency, revenue was NOK 35 million, a 50% increase.

• EBITDA improved to NOK 1.6 million from NOK -3.7 million; EBITDA margin was 5% versus -16% last year.

• Net profit was NOK 0.6 million, up from a loss of NOK 3.1 million in Q1 2025.

• Cash and short-term investments stood at NOK 264 million, with no interest-bearing debt and a 94% equity ratio.

• Operating expenses rose 10% to NOK 33.5 million, mainly due to higher personnel and property expenses.

Outlook and guidance

• Sustained double-digit growth and margin expansion targeted, with focus on scaling commercial operations and building RNA therapeutics as a third growth pillar.

• Visible 2026 revenue from key diagnostic customers and commercial stage GMP momentum continue to build.

• RNA therapeutics identified as the most significant medium-term growth opportunity, with new enzyme launches planned.

• Order phasing effects, especially in APAC and the U.S. East Coast, are expected to normalize in H2.

• Company remains vigilant regarding geopolitical and macroeconomic risks, maintaining operational flexibility.